Business Wire
24 Jun 2026, 18:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Angelini Pharma S.p.A. has proposed to acquire Catalyst Pharmaceuticals (CPRX) for $31.50 per share in cash. — Definitive acquisition offers at a premium typically trigger immediate positive price action for the target company.
+0.80The law firm Kahn Swick & Foti, LLC is investigating whether the sale price and process for Catalyst Pharmaceuticals are adequate. — Lawsuits challenging merger terms can create uncertainty or slight delays, though they often aim to increase the buyout price.
-0.20Which stocks this story touches
The company is facing a legal investigation into whether the sale price and process are adequate for shareholders.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
8h ago
